

# The use of alternative therapies in treating children with attention deficit hyperactivity disorder



Français en page 721

## OBJECTIVES

The objectives of the present statement are to:

- Provide an overview of alternative therapies commonly used in attention deficit hyperactivity disorder (ADHD).
- Review the pharmacology and toxicology of alternative medicines for ADHD.
- Discuss the available evidence about the efficacy of alternative therapies for ADHD.

## INTRODUCTION

ADHD is a common and complex disorder for which no specific neuroanatomical, physiological, biochemical or psychological origin has been identified. Despite the effectiveness and relative safety of stimulant medications, many parents are concerned about giving their child a psychoactive, 'mind-altering' medication for what is likely to be a long period of time. As with many chronic diseases of childhood, parents have turned to complementary and alternative medicine (1). There is a plethora of information on alternative therapies for ADHD in the mainstream media and on the Internet. Evidence-based reports were identified from the MEDLINE database and references of review articles published in peer-reviewed literature (Table 1).

## DIETARY MANAGEMENT

Dietary interventions are the most popular alternative therapies in ADHD (2) and primarily include the following types of diets.

### Elimination diets in ADHD

**The Feingold diet:** In his book, *Why Your Child is Hyperactive* (3), Feingold reported that when treated with the salicylate and additive-free diet, 50% of children with ADHD achieved a "full response", and showed a return to symptoms when the offending food artificial additives were reintroduced. The effects of this diet have been reviewed in

controlled studies (4-12), showing that improvements were not consistent, occurring generally on parental report, but rarely substantiated by laboratory measures (13,14).

### Elimination of food allergens

Over the past 15 years, double-blind, placebo controlled food allergen challenge studies have shown some results on more differentiated outcomes (15-18). This recent research led to the following conclusions (19).

- Appropriate elimination diets are more likely to improve behaviour in younger children with atopic histories, a family history of migraine, and a family history of food reactivity.
- Common dietary allergens are implicated (milk, nuts, fish, wheat and soy) as well as additives.
- Specific target behaviours should be considered.

### Restriction of sugar and aspartame

There is a tenacious 'myth' that sugar and aspartame intake can cause hyperactive behaviour. Although Prinz et al (20) found correlations between the amount of sugar consumed and levels of observed inappropriate behaviour, no causality could be demonstrated. Further challenge studies (21-24) showed no effect of dietary sucrose or aspartame on children's behaviour.

Another popular theory comes from Crook's *The Yeast Connexion* (25), which postulates that chronic candidiasis and candida toxin production is responsible for hyperactivity. Treatment based on this theory includes the use of anti-fungal agents, and a diet free of any sugar source that could promote yeast growth, and any foods made with or contaminated by molds and yeast (eg, bread, cheese, processed foods, dried fruits). This has not been scientifically validated.

### Dietary supplements

**Megavitamin therapy:** A double-blind, placebo controlled, crossover study of megavitamin treatment (combination of

**TABLE 1**  
**Description of studies**

Intervention	Design	Number of patients (selection and/or measures)	Results	Comments
<b>Dietary management</b>				
<b>Feingold diet</b>				
Conners (4)	DBCO	15 (DSM-II rating scales)	Improvement on teacher questionnaires only	Pronounced order effects
Harley (5)	DBCO	36 (Conners P-TQ, observation-neuro, psychological tests)	No change on objective laboratory measures Behavioural improvement	Pronounced order effects
Williams (6)	RDBCO	26 (Conners P-TQ, rating subscales)	Improved on medication Slight improvement on diet plus medication	Criteria-dependent effects
Levy (7)	DBCOC	22 (Psychiatric Dx Conners-WISC)	Equivocal improvement on parent questionnaire	Challenge with tartrazine only
Swanson (8)	Control challenge	40 (Conners P-TQ) Learning tests	No behavioural differences Worse on one laboratory task after challenge	Very high dose of colour challenge
Weiss (9)	DBCOC	22 (no diagnosis, parent observation)	No change in behaviour inventories	Repeated high dose challenge
Mattes (10)	DBCOC RO	11 (DSM-III)	No differences	Repeated high dose challenge
Pollock (11)	DBPCC	19 (Food additive behaviour effects, Conners ratings)	No behavioural differences reported by parents	Adverse effect on Conners ratings
Rowe (12)	DBPC	54 (Reactors or not by parent opinion, behaviour/Conners)	Behavioural changes	Dose response effect
<b>Allergen-free diet</b>				
Egger (15)	DBCOPC	31 (Conners scale Actometer/figures matching test)	Changes of behaviour and psychological tests	Treatment order effect
Kaplan (16)	WSCOPC	24 (DSM-III, Conners ASQ and physical symptoms)	Behavioural improvement reported by parents	Preschoolers only; sleep improvement
Carter (17)	DBPCC RO	19 (DSM-III, Conners PQ, tests learning/matching)	Behavioural changes reported by parents Changes in cognitive tests	Selection after an open trial
Boris (18)	DBPCC RO	16 (DSM-III-R Conners APQ)	Behavioural changes reported by parents	Higher change in atopic cases
<b>Sugar</b>				
Prinz (20)	Correlational study	28 (WWP scale behaviour video)	Aggressive behaviour is increased with sugar	Hyperactive children only
Wolraich (21)	PCC RO	16 (Conners P-TQ behaviour, learning and memory tasks)	No differences between challenge and placebo	Hyperactive children only
Milich (22)	PCC	16 (DSM-III behaviour, reading, math tasks)	No differences in learning or behaviour	Concurrent behaviour intervention
Wolraich (23)	DBPCC L-S Design RO	25 normal age 3-5, 23 sugar-sensitive age 6-10 (cognitive and behavioural tests)	No differences on behaviour or cognitive function	High doses Sugar-sensitivity by parent opinion
<b>Megavitamin</b>				
Haslam (26)	DBCOPC	7/41 (open trial DSM-III-Conners)	No differences on behaviour	Potential hepatotoxicity

continued on next page

**TABLE 1 (continued)**  
**Description of studies**

<b>Intervention</b>	<b>Design</b>	<b>Number of patients (selection and/or measures)</b>	<b>Results</b>	<b>Comments</b>
<b>Iron</b>				
Sever (28)	Open trial	14 (DSM-III-R Conners P-TQ)	Improvement of behaviour	Parental report Not by teacher
<b>Magnesium</b>				
Starobrat-Hermelin (29)	Cohort and control	75 (DSM-IV Conners P-TQ)	Improvement of behaviour	Not blinded/ randomized comorbidity
<b>Pyridoxin</b>				
Coleman (30)	DBPC Randomized	6 (DSM-II Conners P-TQ)	Improvement of behaviour	Trend with order effect
<b>Zinc</b>				
Arnold (32)	DBCOPC L-S design RO	18 (DSM-III Conners P-TQ)	Linear relationship with amphetamine, Efamol benefit with borderline zinc	Post-hoc study (cf Arnold [38])
<b>Essential fatty acids</b>				
Aman (37)	DBCOPC Randomized	31 (RBPCparent/Conners TQ Learning/motor)	Improvement 2/42 variables of cognitive/motor tests and behaviour	Grant from Efamol Ltd Parent rating
Arnold (38)	DBCOPC L-S design RO	18 (DSM-III Conners P-TQ)	No difference between Efamol, amphetamine, or placebo on most measures	Trend with order effect Efamol grant
Voigt (39)	DBPC Randomized	63 (DSM-IV TOVA/Colour Trails CBCL, Conners)	No improvement despite increased plasma phospholipid DHA	Stimulants withheld 24 h pretesting
<b>Nootropics</b>				
Lewis (42)	DBPC RO	74 (school problems, psychometric tests, WWP behaviour scale)	As effective as methylphenidate	Loose entry criteria, not all ADHD
<b>Herbs</b>				
<b>Kava</b>				
Volz (50)	DBPC Randomized Multicentre	101 (DSM-III-R Anxiety Scale)	Short term and long term improvement of anxiety	Adults only heterogeneous patient-group
<b>Ginkgo biloba</b>				
Hornig (52)	Descriptive	Not specified	Improvement of vigilance	Adults only
<b>Antioxidants</b>				
<b>Pycnogenol</b>				
Greenblatt (57)	Case studies	More than 100	Improved school performance	No description of patients
<b>Melatonin</b>				
Smits (60)	RPC	25 (Conners scale actigraphy)	Improved sleep	Abstract only
<b>Oculovestibular treatment</b>				
Arnold (62)	Split-sample L-S crossover Randomized	30 (DSM-III, Conners P-TQ hyperkinetic scale)	Improvement of hyperkinetic scale	Trend only
<b>Homeopathy</b>				
Lamont (63)	DBCOPC Not truly	43 (Psychology tests not stated)	Improved behaviour on hyperkinetic 5-point scale	Treatment not standardized comorbidity
<b>Auditory stimulation</b>				
Abikoff (64)	Controlled RO	40 (DSM-III-R arithmetic test)	Improvement of arithmetic skills in ADHD patients	Group order interaction

*continued on next page*

**TABLE 1 (continued)**  
**Description of studies**

Intervention	Design	Number of patients (selection and/or measures)	Results	Comments
<b>EEG biofeedback</b>				
Lubar (71)	Open trial	23 (DSM-III-R, EEG, TOVA, behaviour scale WISC-R)	Improvement of TOVA, behaviour, and WISC-R	Three subsets (19,13,10) No EEG correlation
Rossiter (73)	Controlled for age, sex, IQ Not blinded Not randomized	18 (DSM-III-R TOVA behaviour scale)	Improvement of TOVA and behaviour	No differences with psychostimulants
Linden (74)	Randomized controlled study with waiting list	18 (DSM-III-R, IQ subtests, Conners PQ)	Improvement of attention behaviour and IQ scores	Some patients with learning disorders

*CBCL Child Behaviour Checklist; Conners PTQ Conners Parent Teacher Questionnaire; DBCO Double-blind, cross over; DBCOC Double-blind, cross over challenge; DBCOPC Double-blind, cross over placebo controlled; DBPC Double-blind placebo-controlled; DBPCC Double-blind placebo-controlled challenge; DSM Diagnostic and Statistical Manual of Mental Disorders; L-S Latin-Square; PCC Placebo-controlled challenge; RBPC Revised Behaviour Problem Checklist; RDBCO Randomized double-blind cross-over; RO Randomized order; RPC Randomized placebo-controlled; TOVA Test of Variables of Attention; WISC Wechsler Intelligence Scale for Children; WSCOPC Within-subject cross-over placebo-controlled; WWP Scale Werry-Weiss-Peter Scale*

B<sub>6</sub>, niacinamide, ascorbic acid and panthotenate) of children with ADHD showed no improvement on behaviour (26). One should also be concerned by reports of toxicity of megavitamin therapy (27) (Table 2).

**Iron:** Proven iron deficiency should be treated. However, an open trial of iron supplementation in noniron-deficient boys with ADHD showed no improvement in teacher behavioural ratings, although parent behavioural ratings improved (28). Because this study was not followed by a controlled clinical trial, there is no support for an indication of routine iron supplementation of children with ADHD.

**Magnesium:** One study showed behavioural improvement in a cohort of children with ADHD and relative deficiency in magnesium (29). However, this isolated report does not justify routine magnesium supplementation in children with ADHD.

**Pyridoxine (vitamin B<sub>6</sub>):** One double-blind study showed a trend in favour of behavioural improvement in children with ADHD receiving pyridoxine compared with methylphenidate and placebo (30). No other study confirmed this trend, and pyridoxine is not recommended unless a deficiency is documented.

**Zinc:** One study found lower serum zinc in healthy, normally nourished children with ADHD, compared with a group of children without ADHD (31). Another study suggested that zinc nutrition may be important for the response of ADHD children to dextroamphetamine, and that the possible benefit of evening primrose oil (gamma-linolenic acid) derives from the improvement or compensation for

borderline zinc nutrition (32). There are no controlled studies, and supplementation beyond the recommended daily allowance is not indicated in the absence of documented deficiency.

**Essential fatty acids:** Some studies have shown that children with ADHD had a higher rate of nonspecific symptoms typical of essential fatty acids deficiency (eg, increased thirst and atopy) (33-35). Evening primrose oil contains over 70% cis-linoleic acid and about 9% cis-gamma linolenic acid, and has been reputed to improve behaviour of hyperactive children (36). Another source of essential fatty acids is fish oil, which contains docosahexaenoic acid, a long chain polyunsaturated fatty acid whose obligate precursor is alpha-linolenic acid. However, three blinded placebo controlled studies on essential fatty acid supplementation in children with ADHD showed minimal or no behavioural improvements (37-39).

#### **Role of nutritional supplementation in the treatment of ADHD**

Children with ADHD may be at an increased risk for marginal deficiency of some micronutrients, because of erratic eating habits and decreased appetite secondary to treatment with stimulant medications. Although no studies support using megadoses of any micronutrient, children with ADHD may need a daily multivitamin and mineral supplement to meet the recommended daily nutritional requirements (40).

#### **Nootropics**

Nootropics are substances reported to enhance mental competence. The most commonly used is piracetam, which acts possibly through the enhancement of dopamine and

**TABLE 2**  
**Side effects and drug interactions**

Therapy	Side effects	Drug interactions
<b>Megavitamins</b>	Hepatotoxicity	
<b>Essential fatty acids</b>	Gastrointestinal symptoms, headaches	None known
<b>Nootropics</b>	Unknown	None known
<b>Herbs</b>		
Valerian	Headaches	Increases sleeping time with pentobarbital
Kava	Muscle weakness, rash, weight loss, increased high density lipoprotein, hematuria	Potentiates benzodiazepines Necrotizing hepatitis with other herbs
Ginkgo biloba	Headaches, dizziness, rash, gastrointestinal symptoms, palpitations	Potentiates anticoagulants
Blue-green algae	Gastrointestinal symptoms, weakness, numbness, tingling	None known
<b>Antioxidants</b>		
Pycnogenol	None known	Prevents platelet aggregation, Not to be used with anticoagulants
Melatonin	Headaches, fatigue, sleepiness, irritability	Proconvulsant effects in children with neurological disabilities Possible suppression of puberty

Data from reference 43

noradrenaline transmission (41). There are no controlled studies to date of piracetam's effect on ADHD. Another nootropic frequently contained in over-the-counter ADHD remedies is deanol, considered to be an acetylcholine precursor. In one double-blind, placebo controlled study, deanol seemed to improve performance in children with learning and behavioural disorders about as much as methylphenidate (42). However, selection criteria were very loose. Children were referred for poor school performance; the sample studied was heterogeneous, with only 49 of 74 children having a clear history of hyperactivity; and there was no measure of core symptoms of ADHD.

### Herbal remedies

These agents have been used for a long time for their sedative or anxiolytic properties as well as their possible enhancement of memory and cognition (43). Sedative herbs are quite popular because of the frequency of sleep problems in children with ADHD (44). The most popular sedative herbs include chamomile (45), lemon balm, valerian, passion flower and hops.

- Herbal teas, which contain chamomile, spearmint, lemon grass, and other herbs and flowers are considered to be a safe and effective way to help a child relax. However, their chronic use because of stress should be considered as a possible sign that the child has an underlying problem that needs to be addressed (43). Some cases have been reported of diminished iron absorption, atopic dermatitis and allergies in children with hay fever (45).
- Valerian has been shown to be more effective than placebo in improving sleep in clinical randomized trials

with adults (46). However, to date there have been no controlled trials to evaluate valerian in paediatric sleep problems or ADHD. Side effects of valerian are limited to gastrointestinal upset and headache and this product is on the United States Food and Drug Administration's "Generally Recognized As Safe" list (FDA's GRAS list). The use of valerian and lemon balm combinations has been studied in randomized controlled trials in adults with sleep disorders and insomnia with positive results and without daytime sedation or rebound phenomena (47). Lemon balm has not been studied in children with sleep disorders or ADHD. This compound is on the FDA's GRAS list, but caution should be exercised in patients with Grave's disease because of a possible inhibition of thyroid hormones (43).

- Passion flower is used to treat insomnia in adults (48). In combination with valerian, it has been shown in a randomized controlled trial to benefit patients with adjustment disorders and anxious mood. Hypersensitivity vasculitis and altered consciousness have been reported.
- Hops is used as a mild sedative and/or hypnotic agent, but there are no clinical studies of its use for insomnia or anxiety disorders. Allergy and disruption of menstrual cycles have been reported (48).
- Kava is reputed to have anxiolytic, sedative and muscle relaxant properties, without adverse effects on cognitive function or mental acuity. Several clinical trials suggest that kava lactones may be useful in managing anxiety and tension (49). There are no clinical trials about the use of kava in

**TABLE 3**  
**Selected Web sites for further information**

---

Independent evaluation of various products < <a href="http://www.consumerlab.com">www.consumerlab.com</a> >
A commercial site with many articles and references < <a href="http://www.lef.org">www.lef.org</a> >
National Institute of Health Office of Dietary Supplements < <a href="http://dietary-supplements.info.nih.gov/">http://dietary-supplements.info.nih.gov/</a> >
National Center for Complementary and Alternative Medicine < <a href="http://nccam.nih.gov/">http://nccam.nih.gov/</a> >
Health Canada Web site on Natural Products < <a href="http://www.hc-sc.gc.ca/hpb/onhp/">www.hc-sc.gc.ca/hpb/onhp/</a> >

---

ADHD. Kava use has been associated with side effects that include an itchy, scaly rash (kava dermatopathy), muscle weakness, coordination problems and serious liver dysfunction. A safety assessment conducted by Health Canada resulted in a stop-sale order issued in August 2002 for all products containing kava (50).

- Ginkgo biloba is commonly used for peripheral vascular disease, cerebral ischemia and intermittent claudication. Mechanisms of action include vasoregulating activity, platelet activating factor antagonism, changes in neuron metabolism, and free-radical scavenging properties (51). Because of promising effects on adult cognition, concentration and memory (52), ginkgo formulations are used for treating ADHD, but no systematic studies have been reported. Side effects include headache, dizziness, palpitations, gastrointestinal upset and allergic skin reactions (51). Ginkgo should not be used with anticoagulants or antiplatelet agents (such as acetylsalicylic acid) and should be avoided in patients with bleeding disorders (51).
- Blue-green algae are a source of B-complex vitamins, iron, calcium, potassium, magnesium and all 22 amino acids (43). There are no clinical trials of blue-green algae in ADHD. Algae may get contaminated by microbes, heavy metals, sewage and animal feces. Moreover, some species produce their own toxins. Main side effects include nausea, diarrhea, weakness, numbness and tingling (53).
- St John's wort is used as a herbal antidepressant, and a recent meta-analysis showed that it was as effective as standard antidepressants, with fewer side effects (54). There are no clinical trials on the use of St John's wort in ADHD. Recent reports have suggested that there are interactions with various prescribed drugs (theophylline, warfarin, cyclosporine, indinavir, oral contraceptives), possibly by activation of the hepatic isoenzyme 3A4 of cytochrome P450 (55).

Studies comparing herb therapy with conventional treatment are difficult to conduct, mainly because herbal preparations are not standardized, and many questions arise about the purity, reliability, safety and toxicity of these products (56).

### Antioxidants

In addition to ginkgo, other popular antioxidants are pycnogenol and melatonin.

- Pycnogenol has recently been advocated for the treatment of ADHD under the speculation that it is a potent antioxidant and free radical scavenger with beneficial effects on the brain because neurons are rich in docosahexanoic acid (57). There is no scientific evidence to support that assertion (58). Pycnogenol prevents platelet aggregation and should not be used with anticoagulants (43).
- Melatonin is a powerful antioxidant with immunological and neuroprotective effects. It has been successful in treating sleep problems in children with ADHD (59,60). Side effects include reduced daytime alertness, increased fatigue, sleepiness, headache and irritability with high doses (43).

### VISION THERAPY AND OCULOVESTIBULAR TREATMENT

There is no support for claims that dyslexia and secondary ADHD can be alleviated by specific ocular exercises or coloured lenses (61). A study comparing vestibular stimulation with visual stimulation and with combined vestibular and visual stimulation failed to show significant differences between treatments (62). Children's vision should be checked regularly and any concerns should be addressed by an ophthalmologist.

### HOMEOPATHY

Homeopathy is a therapeutic system that purports to restore 'vital energies', by using extreme dilutions of plant, animal or mineral extracts highly individualized to the patient's symptoms. One recent placebo controlled study demonstrated significant behaviour improvement in children with ADHD receiving homeopathic treatment (63). However:

- Patients were assigned to placebo or homeopathy alternately in the order they were referred to the investigator for testing.
- The investigator was not blind to treatment.
- Many patients presented with comorbidity (phobia, post-traumatic stress disorder, manic symptoms).
- The evaluation scale was not validated.
- Children who were not improving after 10 days on one homeopathic prescription received a second and, if needed, a third homeopathic prescription.

## AUDITORY STIMULATION:

### TOMATIS METHOD OF SOUND TRAINING

There is a growing interest in the role of music in emotional and cognitive processes, and its applications in medicine and education. In a recent controlled study (61), boys with ADHD improved their arithmetic solving skills when they were listening to favourite music. However, there was a significant group order interaction, indicating that arithmetic performance was improved only in the group who received music as the first experimental condition. The Tomatis Method of Sound Training is based on the hypothesis that focus and attention can be improved with a combination of auditory stimulation and listening training, using high frequency modifications of human voice and classical music that are transmitted through an 'electronic ear'. Although there are claims of improvement in ADHD, there have been no controlled studies to date. The high intensity of the intervention (at least 75 sessions), and the inclusion of social and academic skills training in the program could be responsible for most of the improvement (40).

### BIOFEEDBACK

The goal of biofeedback is to facilitate the patient's physiological and psychological self-regulation. Electrical or electromechanical equipment is used to measure and then feedback information about physiological processes to the patient who is given instructions about modulating one of the physiological parameters in a desired direction (65).

Electromyographical biofeedback has been used in ADHD, the assumption being that teaching general relaxation will help to reduce the hyperactivity symptoms. Results have been equivocal, due to small samples, lack of control groups, and confounding independent variables such as additional treatments (66).

Quantitative electroencephalography has documented electroencephalogram (EEG) differences between children with ADHD and non-ADHD children (67). Children with ADHD generally display over frontoparietal regions elevations of slow wave theta and/or alpha activity and diminished posterior beta activity (67,68).

Neurofeedback, also called EEG biofeedback training, is designed to enhance certain types of EEG activity and decrease other types of EEG activity when it occurs concurrently. Auditory and/or visual signals proportional to the relevant EEG measure are presented to the child. Because the goal in children with ADHD consists of decreasing theta wave activity and increasing sensorimotor rhythm or beta wave activity, a tone may come on when the theta amplitude drops below a preset threshold, while a second tone may come on when the sensorimotor rhythm or beta amplitudes rise above a given value. Cognitive tasks are used along with auditory neurofeedback to promote generalization (69).

Studies of neurofeedback in the 1970s and 1980s generally used a pre- and post-treatment testing design, or an ABA reversal design (experimental condition A, followed by experimental condition B, followed by experimental

condition A), with the subject as his/her own control. Sample size was small, limiting generalizability of reported sustained improvements in social and academic behaviour for substantial periods of time after treatment (70).

More recent studies of the past 10 years have confirmed earlier results of post-treatment improvement (71,72). One study comparing neurofeedback to the use of psychostimulants with well-matched experimental and control groups demonstrated significant post-treatment improvement of Test of Variables of Attention scores in both groups (73). Another study compared the effect of neurofeedback with a waiting list control condition, and showed a significant intelligence quotient (IQ) increase in the experimental group, and reduced inattentive behaviours, but aggressive and/or defiant behaviours did not differ in both groups. However, EEG data were not available, and improvements may have occurred through behavioural methods (74).

Further research is needed with larger samples and appropriate control groups, with a thorough evaluation of confounding factors, placebo effects, and selection and information biases. One should keep in mind the ethical issue of a 'false-feedback' design in the face of the commitment required from the children and their families, and the potential for discouragement (75). However, neurofeedback offers an alternative for patients who present significant side effects with stimulant medication, show a poor treatment response or refuse to consider medication (40).

### HYPNOTHERAPY

Hypnotherapy allows the child to gain a sense of control, increase self-esteem and competence, and reduce stress. Children usually readily accept the suggestion, and hypnosis bridges the child's inner world of imagination and therapeutic change. Hypnotherapy is particularly helpful when integrated into a multimodal treatment context and adapted to the child's developmental age (76). Although there are no studies showing that hypnotherapy significantly improves the core symptoms of children with ADHD, therapeutic efficacy has been reported in associated symptoms such as sleep disturbances or tics (77).

### ROLE OF THE PHYSICIAN

The physician is responsible for establishing a diagnosis of ADHD and other comorbidities through a standard medical evaluation, and carefully discuss the standard treatment options. The physician should be aware that parents may use alternative therapies in ADHD children, should ask about these at follow-up visits, and should be prepared to share information with families (Table 3). The physician should provide balanced advice on a range of treatment options, identify risks or potential harmful effects, and inform patients about placebo effects and the need for controlled studies. It is important to establish and maintain a trusting relationship with families (78).

## SUMMARY

- Individualized dietary management may be effective in a small selected group of children with allergic symptoms or migraine headaches.
- Trace element supplementation may be beneficial when specific deficiencies are present.
- Nootropics have a role in neurotransmission, but that is not specific to ADHD.
- Herbs have sedative and anxiolytic properties and may play a role in memory and cognition. Side effects and interactions with other medications should be discussed with parents.
- Antioxidants have neuroprotective effects, but they are not specific to ADHD. Parents should be warned about side effects and interactions with other medications.
- Biofeedback involves a substantial commitment from the child and the family, and may be offered in cases where medication is not suitable (poor response, significant side effects, parental and/or child refusal).
- Hypnotherapy may be helpful in controlling secondary symptoms.
- There is no scientific evidence to support vision therapy, oculovestibular treatment or sound training.

## REFERENCES

1. Spiegelblatt L, Laine-Ammara G, Pless IB, Guyver A. The use of alternative medicine by children. *Pediatrics* 1994;94:811-4.
2. Stubberfield TG, Parry TS. Utilization of alternative therapies in attention-deficit hyperactivity disorder. *J Paediatr Child Health* 1999;35:450-3.
3. Feingold BF. *Why Your Child is Hyperactive*. New York: Random House, 1975:71-8.
4. Connors CK, Goyette CH, Southwick DA, Lees JM, Andrunolis PA. Food additives and hyperkinesis: A controlled double-blind experiment. *Pediatrics* 1976;58:154-66.
5. Harley JP, Ray RS, Tomasi L, et al. Hyperkinesis and food additives: Testing the Feingold hypothesis. *Pediatrics* 1978;61:818-28.
6. Williams JI, Cram DM, Tausig FT, Webster E. Relative effects of drugs and diet on hyperactive behaviors: An experimental study. *Pediatrics* 1978;61:811-7.
7. Levy F, Dumbrell S, Hobbes G, Ryan M, Wilton N, Woodhill JM. Hyperkinesis and diet: A double-blind crossover trial with a tartrazine challenge. *Med J Aust* 1978;1:61-4.
8. Swanson JM, Kinsbourne M. Food dyes impair performance of hyperactive children on a laboratory learning test. *Science* 1980;207:1485-6.
9. Weiss B, Williams JH, Margen S, et al. Behavioral responses to artificial food colors. *Science* 1980;207:1487-9.
10. Mattes JA, Gittelman R. Effects of artificial food colorings in children with hyperactive symptoms: A critical review and results of a controlled study. *Arch Gen Psychiatry* 1981;38:714-8.
11. Pollock I, Warner JO. Effect of artificial food colours on childhood behaviour. *Arch Dis Child* 1990;65:74-7.
12. Rowe KS, Rowe KJ. Synthetic food coloring and behavior: A dose response effect in a double-blind, placebo-controlled, repeated measures study. *J Pediatr* 1994;125:691-8.
13. Kavale KA, Forness SR. Hyperactivity and diet treatment: A meta-analysis of the Feingold hypothesis. *J Learn Dis* 1983;16:324-30.
14. Wender EH. The food-additive free diet in the treatment of behavior disorders: A review. *J Dev Behav Pediatr* 1986;7:35-42.
15. Egger J, Graham PJ, Carter CM, Gumley D, Soothill JF. Controlled trial of oligoantigenic treatment in the hyperkinetic syndrome. *Lancet* 1985;i:540-5.
16. Kaplan BJ, McNicol J, Conte RA, Moghadam HK. Dietary replacement in preschool-aged hyperactive boys. *Pediatrics* 1989;83:7-17.
17. Carter CM, Urbanowicz, Hemsley R, et al. Effects of a few food diet in attention deficit disorder. *Arch Dis Child* 1993;69:564-8.
18. Boris M, Mandel F. Foods and additives are common causes of the attention deficit hyperactivity disorder in children. *Ann Allergy* 1994;72:462-7.
19. Breakey J. The role of diet and behaviour in children. *J Paediatr Child Health* 1997;33:190-4.
20. Prinz RJ, Roberts WA, Hantmann E. Dietary correlates of hyperactive behavior in children. *J Consult Clin Psychol* 1980;48:760-9.
21. Wolraich M, Milich R, Stumbo P, Schultz F. Effects of sucrose ingestion on the behavior of hyperactive boys. *J Pediatr* 1985;106:675-81.
22. Milich R, Pelham WE. Effects of sugar ingestion in the classroom and playground behavior of attention deficit disordered boys. *J Consult Clin Psychol* 1986;54:714-8.
23. Wolraich ML, Lindgren SD, Stumbo PJ, Stegink LD, Appelbaum MI, Kiritsy MC. Effects of diets high in sucrose or aspartame on the behavior and cognitive performance of children. *N Engl J Med* 1994;330:301-7.
24. Milich R, Wolraich M, Lindgren S. Sugar and hyperactivity: A critical review of empirical findings. *Clin Psychol Rev* 1986;6:493-513.
25. Crook WG. *The Yeast Connexion*. New York: Vintage Books, 1986.
26. Haslam R. Is there a role for megavitamin therapy in the treatment of attention deficit hyperactivity disorder? *Adv Neurol* 1992;58:303-10.
27. Canadian Paediatric Society Nutrition Committee. Megavitamin and megamineral therapy in childhood. *CMAJ* 1990;143:1009-13.
28. Sever Y, Ashkenazi A, Tyano S. Iron treatment in children with attention deficit disorder. A preliminary report. *Neuropsychobiology* 1997;35:178-80.
29. Starobrat-Hermelin B, Kozielc T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD): Positive response to magnesium oral loading test. *Magnes Res* 1997;10:149-56.
30. Coleman M, Steinberg G, Tippett J, et al. A preliminary study of the effect of pyridoxine administration in a subgroup of hyperkinetic children: A double-blind crossover comparison with methylphenidate. *Biol Psychiatry* 1979;14:741-51.
31. Toren P, Eldar S, Sela BA, et al. Zinc deficiency in attention-deficit hyperactivity disorder. *Biol Psychiatry* 1996;40:1308-10.
32. Arnold LE, Pinkham SM, Votolato N. Does zinc moderate essential fatty acid and amphetamine treatment of attention-deficit/hyperactivity disorder? *J Child Adolesc Psychopharmacol* 2000;10:11-117.
33. Colquhoun I, Bunday S. A lack of essential fatty acids as a possible cause of hyperactivity in children. *Med Hypotheses* 1981;7:673-9.
34. Mitchell EA, Aman MG, Turbott SH, Manku M. Clinical characteristics and serum essential fatty acid levels in hyperactive children. *Clin Pediatr* 1987;26:406-11.
35. Stevens LJ, Zentall SS, Deck JL, et al. Essential fatty acid metabolism in boys with attention-deficit hyperactivity disorder. *Am J Clin Nutr* 1995;62:761-8.
36. Briggs CJ. Evening Primrose. *Can Pharm J* 1986;119:249-54.
37. Aman MG, Mitchell EA, Turbott SH. The effects of essential fatty acid supplementation by Efamol in hyperactive children. *J Abnorm Child Psychol* 1987;15:75-90.
38. Arnold LE, Kleykamp D, Votolato NA, Taylor WA, Kontras SB, Tobin K. Gamma-linoleic acid for attention-deficit hyperactivity disorder: Placebo-controlled comparison to D-amphetamine. *Biol Psychiatry* 1989;25:222-8.
39. Voigt RG, Llorent AM, Jensen CL, Fraley JK, Berretta MC,

- Heird WC. A randomized, double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. *J Pediatr* 2001;139:189-96.
40. Baumgaertel A. Alternative and controversial treatments for attention-deficit/hyperactivity disorder. *Pediatr Clin North Am* 1999;46:977-92.
  41. Gouliava AH, Senning A. Piracetam and other structurally related nootropics. *Brain Res Rev* 1994;19:180-222.
  42. Lewis JA, Young R. Deanol and methylphenidate in minimal brain dysfunction. *Clin Pharmacol Ther* 1975;17:534-40.
  43. Chan E, Gardiner P, Kemper KJ. "At least it's natural...". Herbs and dietary supplements in ADHD. *Contemp Pediatr* 2000;17:116-30.
  44. Day HD, Abmayr SB. Parent reports of sleep disturbances in stimulant-medicated children with attention-deficit hyperactivity disorder. *J Clin Psychol* 1998;54:701-16.
  45. Berry M. The chamomiles. *Pharm J* 1995;254:191-3.
  46. Lindhal O, Lindwall L. Double blind study of a valerian preparation. *Pharmacol Biochem Behav* 1989;32:1065-6.
  47. Dressing H, Riemann D. Insomnia: Are valerian/Melissa combinations of equal value to benzodiazepine? *Therapiewoche* 1992;42:726-36.
  48. Wong AHC, Smith M, Boon HS. Herbal remedies in psychiatric practice. *Arch Gen Psychiatry* 1998;55:1033-44.
  49. Volz HP, Kieser M. Kava-kava extract WS 1940 vs. Placebo in anxiety disorders – A randomized placebo-controlled 25-week outpatient trial. *Pharmacopsychiatry* 1997;30:1-5.
  50. Health Canada Online. <[http://www.hc-sc.gc.ca/english/protection/warnings/2002/2002\\_56e.htm](http://www.hc-sc.gc.ca/english/protection/warnings/2002/2002_56e.htm)> (Version current at October 30, 2002).
  51. Kleijnen J, Knipschild P. Ginkgo biloba. *Lancet* 1992;340:1136-9.
  52. Hornig M. Ginkgo biloba for attention and memory disorders. *Alt Med Alert* 1998;1:137-9.
  53. NCAHF. Growing concerns over blue-green algae. *National Council Against Health Fraud Newsletter* 1996;1:1.
  54. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression – An overview and meta-analysis of randomized clinical trials. *BMJ* 1996;313:253-8.
  55. Ernst E. Second thoughts about safety of St John's wort. *Lancet* 1999;354:2014-5.
  56. Kemper KJ, Cassileth B, Ferris T. Holistic pediatrics: A research agenda. *Pediatrics* 1999;103:902-3.
  57. Greenblatt J. Nutritional supplements in ADHD. *J Am Acad Child Adolesc Psychiatry* 1999;38:1209-10. (Lett)
  58. Horrigan JP. Comment. *J Am Acad Child Adolesc Psychiatry* 1999;38:1210-1.
  59. Jan JE, O'Donnell ME. Use of melatonin in the treatment of paediatric sleep disorders. *J Pineal Res* 1996;21:193-9.
  60. Smits M, Nagtegaal E, Valentijn S. Melatonin for chronic sleep onset insomnia in children with attention deficit hyperactivity disorder: Randomized placebo controlled trial. *J Neurol Neurosurg Psychiatry* 1999;67:840.
  61. American Academy of Pediatrics. Learning disabilities, dyslexia, and vision: A subject review. *Pediatrics* 1998;102:1217-9.
  62. Arnold LE, Clark DL, Sachs LA, Jakim S, Smithies C. Vestibular and visual rotational stimulation as treatment for attention deficit and hyperactivity. *Am J Occup Ther* 1985;39:84-91.
  63. Lamont J. Homeopathic treatment of attention deficit hyperactivity disorder. A controlled study. *Br Homeopath J* 1997;86:196-200.
  64. Abikoff H, Courtney ME, Szeibel PJ, Koplewicz HS. The effects of auditory stimulation on the arithmetic performance of children with ADHD and nondisabled children. *J Learn Disabil* 1996;29:238-46.
  65. Culbert TP, Kajander RL, Reaney JB. Biofeedback with children and adolescents: Clinical observations and patient perspectives. *J Dev Behav Pediatr* 1996;17:342-50.
  66. Lee SW. Biofeedback as a treatment for childhood hyperactivity: A critical review of the literature. *Psychol Rep* 1991;68:163-92.
  67. Mann C, Lubar JF, Zimmerman AW, Millar CA, Muenchen RA. Quantitative analysis of EEG in boys with attention deficit-hyperactivity disorder: Controlled study with clinical applications. *Pediatr Neurol* 1992;8:30-6.
  68. Lazarro I, Gordon E, Whitmont S. Quantified EEG activity in adolescent attention deficit hyperactivity disorder. *Clin Electroencephalogr* 1998;29:37-42.
  69. Nash JK. Treatment of attention deficit hyperactivity disorder with neurotherapy. *Clin Electroencephalogr* 2000;31:30-7.
  70. Lubar JF. Discourse on the development of EEG diagnostics and biofeedback treatment for attention deficit/hyperactivity disorders. *Biofeedback Self Regul* 1991;16:201-25.
  71. Lubar JF, Swartwood MO, Swartwood JN, O'Donnell P. Evaluation of the effectiveness of EEG neurofeedback training for ADHD in a clinical setting as measured by changes in T.O.V.A. scores, behavioral ratings, and WISC-R performance. *Biofeedback Self Regul* 1995;20:83-99.
  72. Alhambra MA, Fowler TPP, Alhambra AA. EEG biofeedback: A new treatment option for ADD/ADHD. *J Neurother* 1995;1:39-43.
  73. Rossiter TR, LaVaque TJ. A comparison of EEG biofeedback and psychostimulants in treating attention deficit/hyperactivity disorders. *J Neurother* 1995;1:48-59.
  74. Linden M, Habib T, Radojevic V. A controlled study of the effects of EEG biofeedback on cognition and behavior of children with attention deficit disorder and learning disabilities. *Biofeedback Self Regul* 1996;21:35-49.
  75. Baydala L, Wikman E. The efficacy of neurofeedback in the management of children with attention deficit/hyperactivity disorder. *Paediatr Child Health* 2001;6:451-5.
  76. Sugarman IL. Hypnosis in a primary care practice: Developing skills for the "new morbidities". *J Dev Behav Pediatr* 1996;17:300-5.
  77. Kohen DP. Applications of relaxation and mental imagery (self-hypnosis) for habit problems. *Pediatr Ann* 1991;20:136-44.
  78. American Academy of Pediatrics. Committee on Children with Disabilities. Counselling families who choose complementary and alternative medicine for their child with chronic illness or disability. *Pediatrics* 2001;107:598-601.

#### PSYCHOSOCIAL PAEDIATRICS COMMITTEE

**Members:** Drs Anne-Claude Bernard-Bonnin, Département de pédiatrie, Hôpital Sainte-Justine, Montréal, Québec; Kim Joyce Burrows, Kelowna, British Columbia; Anthony Ford-Jones, Department of Pediatrics, Joseph Brant Memorial Hospital, Burlington, Ontario; Sally Longstaffe, Child Development Clinic, Children's Hospital, Winnipeg, Manitoba (chair); Theodore A Prince, General and Developmental Pediatrics, Calgary, Alberta; Sarah Emerson Shea, IWK Health Centre, Halifax, Nova Scotia (director responsible)

**Consultants:** Drs Rose Geist, The Hospital for Sick Children, Toronto, Ontario (Canadian Academy of Child Psychiatry); William J Mahoney, Children's Hospital, Hamilton Health Sciences Centre, Hamilton, Ontario; Peter Nieman, Calgary, Alberta

**Liaisons:** Drs Joseph F Hagan, University of Vermont College of Medicine, Burlington, Vermont (Committee on Psychosocial Aspects of Child & Family, American Academy of Pediatrics); Anton Miller, Sunnyhill Health Centre for Children, Vancouver, British Columbia (Developmental Paediatrics Section, Canadian Paediatric Society)

**Principal author:** Dr Anne-Claude Bernard-Bonnin, Hôpital Sainte-Justine, Montreal, Quebec

---

The recommendations in this statement do not indicate an exclusive course of treatment or procedure to be followed. Variations, taking into account individual circumstances, may be appropriate.

Internet addresses are current at the time of publication.